Targeting treatment resistant malignancies remains a major challenge in oncology. In the present study, we introduce a novel therapeutic compound targeting Activating Transcription Factor 5 (ATF5) through utilization of a novel cell penetrating peptide, termed CP-d/n-ATF5-S1.
Introduction
While recent significant responses for cancer therapy have been achieved in some malignancies, these are often initially impressive, but unfortunately not durable (1, 2) . For other malignancies, such as high-grade primary brain cancers the prognosis is unfavorable even with treatment (3) . Therefore, efforts continue to identify new potential targets for tumor-specific treatments as well as novel therapeutic strategies to exploit these targets.
ATF5 is an example that has been identified as a potential target for cancer treatment but for which no specific therapy has been developed (4, 5) . Activating transcription factor 5 (ATF5; also termed ATFx), is a member of the activating transcription factor/cyclic AMP responsive elementbinding (ATF/CREB) family. A common feature of this family is the presence of a basic leucine zipper (bZIP) domain that promotes DNA binding via the basic region and interactions with other proteins through the leucine zipper (5-7). ATF5 binds to several different promoter elements including the nutrient sensing report element (NRSE) and a novel motif to regulate gene transcription (6, 8) . Full length ATF5 appears to be rapidly degraded via the proteasome and it has the unusual property that it is among a small group of proteins that are selectively translated when eiF2α is phosphorylated (9, 10) .
ATF5 protein levels are increased in a variety of human malignancies, including glioblastoma, breast, pancreatic, lung and colon cancers (11). In contrast, with few exceptions (liver, prostate and testis) ATF5 expression is low in normal tissue of the respective organs. In several tumor types, including glioblastoma and non-small cell lung cancer, ATF5 expression negatively correlates with survival (12,13). In cell culture studies, ATF5 promotes survival by counteracting apoptosis in pro-B lymphocytes deprived of IL-3 or in HeLa cells after growth factor withdrawal (14) . In addition, ATF5 regulates transcription of anti-apoptotic B cell leukemia 2 (Bcl-2) and of Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1), presumably thereby promoting tumor cell survival (13, 15) . Conversely, interference with ATF5 expression or activity yields a marked induction of apoptosis in glioblastoma cells in vitro and in vivo without affecting astrocytes (16, 17) . Moreover, in a transgenic murine model in which endogenous glioblastomas were induced by a PDGF/sh-p53 expressing virus, activation of a dominant/negative (d/n)-ATF5 blocked tumor formation and resulted in regression of formed tumors (17) . Antineoplastic activity of d/n-ATF5 was also reported for breast cancer cells and pancreatic cancer cells in vitro (11, 15, 18) . These findings thus suggest ATF5 as a promising target for a tailored anti-cancer therapy.
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Author Manuscript Published OnlineFirst on April 28, 2016; DOI: 10.1158/1078-0432.CCR- To provide a potential means to target ATF5 in vivo, we designed a d/n-ATF5 linked to a cell penetrating domain (Penetratin) (19) . This recombinant peptide passes the blood brain barrier, enters tumor cells and exerts antineoplastic activity in a rodent transgenic glioma model. In the present study, we assessed the activity and mechanism of action of a similar peptide (CP-d/n-ATF5-S1) that was further modified to reduce its size and that was generated synthetically. In in vitro studies and in in vivo murine xenograft models, CP-d/n-ATF5-S1 shows apoptosis induction over a broad range of recalcitrant human malignancies without apparent effects on non-transformed cells. A novel mechanism of action was found in which the peptide reduces expression of the deubiquitinating enzyme Usp9X, which in turn leads to depletion of Mcl-1 and Bcl-2 and to consequent apoptotic death. The latter findings led us to rationally design and carry out in vitro and in vivo tests of several potential combination therapies with CP-d/n-ATF5-S1 that had enhanced efficacy compared with either agent alone.
Materials and Methods

Ethics statement
All procedures were in accordance with Animal Welfare Regulations and approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.
Reagents
CP-d/n-ATF5-S1, mutated CP-d/n-ATF5-S1 and Penetratin were purchased from CS Bio (Menlo Park, CA). Recombinant TRAIL was from Peprotech (Rocky Hill, NJ). ABT263 was from
Results
CP-d/n-ATF5-S1
CP-d/n-ATF5-S1 is a synthetic 67-amino-acid peptide that was engineered to cross cellular membranes and to specifically interfere with the survival-promoting actions of ATF5 ( Figure 1A ).
The N-terminal has a 16 amino acid Penetratin domain that facilitates cellular penetration (25, 26) . A dominant/negative-sequence follows in which the DNA binding domain of ATF5 is substituted by an amphipathic sequence with a leucine repeat at every seventh residue and then by the human ATF5 basic leucine zipper (bZIP) domain truncated after the first valine (26) (27) (28) (29) . Parallel work has demonstrated that a similar recombinant tagged peptide passes the blood brain barrier, enters intact cells both in vivo and in vitro and promotes selective death of glioma cells (19) . Four independent batches of the peptide (including one under GMP conditions) have had comparable activity. For control purposes, peptides were also synthesized with a penetratin domain alone and in which key leucine residues were mutated to glycine in the d/n portion to reduce binding to potential partners ( Figure 1A) 
CP-d/n-ATF5-S1 depletes endogenous ATF5
Western blot analyses revealed that treatment of cultured tumor cell lines (T98G, MDA-MB-436 and GBM12) with CP-d/n-ATF5-S1 leads to a dose-dependent reduction of endogenous ATF5 protein levels by 3 days (Figure 1B, Suppl. fig. 1B ). In T98G cells this effect was present after 48, but not 24h ( Figure 1B, Suppl. fig. 1A ). RNAseq analysis of T98G glioblastoma cells treated with CP-d/n-ATF5-S1 for 1-3 days showed no significant alteration of ATF5 transcript levels (data not shown). Comparison of endogenous ATF5 levels in T98G cells treated with or without CP-d/n-ATF5-S1 in presence of cycloheximide indicates that the peptide significantly decreases ATF5 protein stability ( Figure 1C and 1D, Suppl. fig. 1C ). In contrast, treatment with Penetratin peptide did not affect ATF5 stability (Suppl. fig. 1D and 1E) . Thus, one action of CP-d/n-ATF5-S1 is loss of endogenous ATF5 caused at least in part by enhanced turnover.
CP-d/n-ATF5-S1 interferes with transcription of known ATF5 downstream targets
CP-d/n-ATF5-S1 treatment for 24h resulted in down-regulation of three known ATF5 target genes (Mcl-1 (13), Bcl-2 (15,30) and asparagine synthetase (8)) at the mRNA-level ( Figure 1E , Suppl. fig. 2 ). However, for Mcl-1 and Bcl-2, this decrease was transitory with mRNA levels returning to baseline by 72h, presumably by compensatory mechanisms. In contrast, CP-d/n-ATF5-S1 did not decrease mRNA levels of Usp9X, a gene not described as transcriptionally regulated by ATF5 ( Figure 1E ).
Research. CP-d/n-ATF5-S1 promotes apoptotic cell death across a wide panel of treatment-resistant human cancer cell lines ATF5 is expressed in a variety of human cancers including glioblastoma (11, 15, 18) . In silico analysis of the Rembrandt data set for glioblastoma shows a significantly worse overall survival in patients harboring an amplification of the ATF5 gene compared with those with ≤ 1.8 copies ( Figure 1F ). Several studies have also reported an inverse relationship between ATF5 protein expression and GBM patient survival (5) .
Inhibition of ATF5 function or expression has marked anti-neoplastic effects in vitro and in vivo (11, 15, 16, 18) . Initially, to assess the activity of CP-d/n-ATF5-S1, T98G, U87MG glioblastoma and HL-60 myeloid leukemia cells were treated for 72h with increasing concentrations of the peptide. CP-d/n-ATF5-S1 yielded a dose-dependent anti-proliferative effect as determined by MTT assay ( Figure 1G and Suppl. fig. 3 ) as well as marked changes in cellular morphology observed by light microscopy ( Figure 1H ). To further assess the mechanism of such effects, we performed annexin V/PI staining across a variety of therapy-refractory human cancer cell lines after treatment with increasing concentrations of CP-d/n-ATF5-S1 for 48h. As shown in Figure   2A -C, Suppl. fig. 4A and 4C and Suppl. fig. 5A , the peptide yielded a strong and dosedependent increase in the fraction of annexin V-positive cells, thus indicating an apoptotic response across a wide and diverse panel of solid and non-solid cancer cells. Moreover, this effect was attenuated by treatment with the pan-caspase inhibitor z-VAD-Fmk in T98G cells (Suppl. fig. 6 ), which is consistent with studies indicating that interference with ATF5 function or expression in tumor cells promotes apoptosis (9, 12) .
To verify whether the effect of the peptide on survival is specifically related to the dominantnegative domain and not to the cell-penetrating domain, we treated T98G cells either with Penetratin alone or CP-d/n-ATF5-S1. In contrast to CP-d/n-ATF5-S1, Penetratin did not markedly increase the fraction of annexin V-positive cells ( Figure 2D and E). Moreover, neither Penetratin nor CP-d/n-ATF5-S1 resulted in a significant induction of apoptosis in human fetal astrocyte cultures ( Figure 1F and G), suggesting that CP-d/n-ATF5-S1 posseses specificity towards cancer cells.
Research. CP-d/n-ATF5-S1 leads to dissipation of mitochondrial membrane potential and activates
caspase-9
Next, we addressed whether activation of apoptosis by CP-d/n-ATF5-S1 is mediated at least in part through a mitochondrial pathway. JC1 staining revealed that peptide treatment leads to a marked reduction of mitochondrial membrane potential ( Figure 2H ) and cleavage (activation) of caspase-9, suggesting that CP-d/n-ATF5-S1 induces apoptosis in part through the mitochondrially-driven apoptotic pathway ( Figure 2I ).
CP-d/n-ATF5-S1 down-regulates anti-apoptotic Bcl-2 and Mcl-1 proteins
Because our findings pointed towards involvement of mitochondria in apoptosis driven by CPd/n-ATF5-S1, we next focused on expression of Bcl-2 family proteins. ATF5 is reported to suppress transcription of anti-apoptotic Bcl-2 and Mcl-1 (13,30). However, at least in T98G cells, there was a rebound of Mcl-1 and Bcl-2 mRNA expression by 3 days of peptide treatment ( Figure 1E ), so it was important to assess protein levels at this time as well. As shown in Figure   3A and Suppl. fig. 7A , Mcl-1 was consistently down-regulated in all lines tested (U87MG, T98G glioblastoma and H1975 non-small cell lung cancer, PANC-1 pancreatic carcinoma, A375 melanoma and PC3 prostate cancer) at 72h of peptide treatment and in some cases, by 48h.
Bcl-2 protein was similarly down-regulated in all but the PC3 cell line. Expression of Bcl-xL, a third member of the anti-apoptotic Bcl-2 family, was altered in some lines (U87MG and T98G), but not in others. Despite a rebound of Mcl-1 and Bcl-2 mRNA levels in T98G cells by 3 days of CP-d/n-ATF5-S1 treatment, expression of the corresponding protein was still decreased in these cells after 6 days of peptide treatment (Suppl. fig. 1F) 
CP-d/n-ATF5-S1 down regulates Bag3 and Usp9X proteins
The observed decreases in Mcl-1 and Bcl-2 proteins at 72h promoted by CP-d/n-ATF5-S1
under conditions in which mRNA levels appear to be unaffected led us to next assess whether the peptide affects expression of Bcl-2 family members by a post-transcriptional mechanism.
For instance, Mcl-1 is stabilized by its chaperone Bcl-2-associated athanogene 3 (Bag3) on one hand and by deubiquitination through the ubiquitin-specific peptidase 9, X-linked (Usp9X) on the other (31,32). Therefore, we determined protein levels of Bag3 and Usp9X in a panel of tumor lines following treatment with increasing concentrations of CP-d/n-ATF5-S1 for 48-72h. Usp9X fmk, indicating that Usp9X depletion is most likely independent of apoptosis and activated caspases as well as of its mRNA levels (Suppl. fig. 8 and Figure 1E ).
Usp9X knockdown induces apoptosis, caspase activation and recapitulates effects of
CP-d/n-ATF5-S1
The consistent effect of CP-d/n-ATF5-S1 on Usp9X expression led us to examine whether silencing Usp9X by another means would be sufficient to phenocopy the pro-apoptotic effect of the peptide. Similarly to cells treated with CP-d/n-ATF5-S1, T98G, U251 and LN229 glioblastoma cells in which Usp9X was silenced with siRNA showed marked reduction in viability as indicated by annexin V/PI or propidium iodide staining ( Figure 3B , Suppl. fig. 9A ).
This was accompanied by a substantial increase in cleavage of caspases-9 and -3 ( Figure 3C , Suppl. fig. 9B ). Additionally, there was significant reduction in Bag3, Mcl-1 and Bcl-2 protein expression in both U251 and T98G cells. Taken together these findings indicate that loss of Usp9X expression promoted by CP-d/n-ATF5-S1 treatment is sufficient to diminish levels of key anti-apoptotic Bcl-2 family members and to induce cell death.
CP-d/n-ATF5-S1 sensitizes for apoptosis induced by BH3-mimetics
Mcl-1 is a major resistance factor towards BH3-mimetics such as ABT737/263/199, and a considerable number of solid malignant tumors, including gliomas, bear high levels of Mcl-1 (33,34). Given that CP-d/n-ATF5-S1 modulates anti-apoptotic members of the Bcl-2 family, especially Mcl-1 and its interacting proteins, we examined whether the peptide may act in a complementary or synergistic fashion with BH3-mimetic agents. We accordingly treated T98G cells with CP-d/n-ATF5-S1 and Bcl-2/Bcl-xL inhibitor ABT263 or the Bcl-2/Bcl-xL/Mcl-1 inhibitor GX15-070. In both instances, combined treatment caused synergistic inhibition of cell viability as assessed by MTT assay ( Figure 4A , Suppl. fig. 10A ). In concordance, cellular morphology was markedly changed in cells subjected to the combination treatments and pointed, as anticipated, towards apoptosis as the underlying mechanism. (Figure 4B ). Because GX15-070 has activities in addition to Bcl-2 family inhibition (35), we focused further combinatorial studies on ABT263. Enhancement of ABT263-mediated apoptosis by CP-d/n-ATF5-S1 was confirmed by annexin V/PI staining. The combination treatment significantly up-regulated the fraction of annexin V-positive cells in T98G, LN229, SF188 (pediatric), NCH644 (glioma stem-like) and GBM12 glioblastoma cultures as well as in PANC-1 pancreatic carcinoma, A375 melanoma, K562 chronic myeloid leukemia (in blast crisis) and HCT116 colorectal cancer cell cultures ( Figure 4C and E, Suppl. fig. 5B and Suppl. fig. 11 ). Consistent with these findings, combined treatment with CP-d/n-ATF5-S1 and ABT263 also enhanced caspase-9 cleavage in T98G cells ( Figure 4F ).
In the context of these experiments, we also assessed a Penetratin-only peptide and a form of CP-d/n-ATF5-S1 mutated in the extended leucine zipper ( Figure 1A ) to diminish its interaction with other proteins. In comparison with CP-d/n-ATF5-S1, the mutated peptide showed markedly less effect on T98G cell morphology either alone or in combination with ABT263 ( Figure 4B ).
The mutated peptide also showed much less effect on apoptosis when applied alone and minimally enhanced apoptosis when combined with the BH3-mimetic ( Figure 4D ). Moreover, combined treatment with the Penetratin peptide and ABT263 resulted in an antagonistic antiproliferative effect (Suppl. fig. 10B ).
Combined CP-d/n-ATF5-S1 and ABT263 treatment promotes enhanced down-regulation of Mcl-1 and Bcl-2 which in turn results in enhanced apoptotic death
We next examined the effect of combined treatment with CP-d/n-ATF5-S1 and ABT263 on expression of anti-apoptotic Bcl-2 family members. As illustrated in Figure 4F , ABT263 alone increased expression of Mcl-1 -a finding that represents a generally accepted mechanism of resistance to BH3-mimetic compounds (34). However when ABT263 was combined with CPd/n-ATF5-S1, Mcl-1 expression was highly suppressed, as was expression of Bcl-2 and Bcl-xL ( Figure 4F ). In contrast, combined treatment with ABT263 and mutated CP-d/n-ATF5-S1 yielded only a slight decrease in Mcl-1 and Bcl-2 expression ( Figure 4F ).
Part of the rationale for combining CP-d/n-ATF5-S1 with ABT263 is that unlike the latter, the former promotes Mcl-1 down-regulation. To examine whether down-regulation of Mcl-1, as occurs with CP-d/n-ATF5-S1, is sufficient to sensitize for ABT263-mediated apoptosis, we silenced Mcl-1 in PANC-1 cells with siRNA prior to treatment with ABT263 (Suppl. fig. 12A ).
Mcl-1 knock-down combined with ABT263 yielded markedly enhanced cleavage of caspases-9 and -3. Additionally, Bag3, Usp9X and Bcl-2 expression was significantly reduced under these conditions compared with cells either silenced for Mcl-1 and/or treated with ABT263 alone.
These observations were also reflected by an enhanced reduction in the fraction of viable LN229 cells remaining after silencing Mcl-1 and treating with ABT263, as compared to treating with either alone (Suppl. fig. 12B ). Similarly, when Usp9X was silenced, LN229 cells became more susceptible to the cytotoxic effects of ABT263 (Suppl. fig. 12C ). Thus, when combined with ABT263, specific knock-down of Mcl-1 and Usp9X (as seen after treatment with CP-d/n-ATF5-S1) suffices to reproduce the molecular profile of combined treatment with CP-d/n-ATF5-S1 and ABT263.
CP-d/n-ATF5-S1 enhances apoptosis induced by the death receptor ligand TRAIL
Next, we examined whether combined treatment with CP-d/n-ATF5-S1 also enhances apoptosis triggered by the extrinsic pathway. Our reasoning was that if the peptide increases sensitivity to the mitochondrial apoptotic pathway, it might complement or enhance mitochondrial-dependent and/or -independent apoptotic actions of a death-promoting ligand. We therefore treated T98G cells with CP-d/n-ATF5-S1 and increasing concentrations of TNF-related apoptosis-inducing ligand (TRAIL). As shown in Figure 5A , treatment with this combination results in an enhanced anti-proliferative effect in the MTT assay compared to control or single treatments. In contrast, the combination of TRAIL with mutated CP-d/n-ATF5-S1 did not show this effect.
Representative microphotographs in Figure 5B illustrate these findings at the level of morphology. Annexin V/PI staining also showed that CP-d/n-ATF5-S1 enhances TRAILmediated apoptosis in T98G cells as well as in LN229 glioblastoma cells and MDA-MB-436 breast cancer cells ( Figure 5C and E). In this assay, mutated CP-d/n-ATF5-S1 alone only slightly increased apoptotic cells when compared to controls and did not enhance TRAILinduced apoptosis ( Figure 5D ). In concordance with these findings, the combination therapy led to reduced expression of full length caspase-3 in T98G cells, presumably due to elevated cleavage of this protein ( Figure 5F ). Mutated CP-d/n-ATF5-S1 did not have this effect. In addition, combined treatment with CP-d/n-ATF5-S1 and TRAIL enhanced down-regulation of Mcl-1 and Bcl-2 expression ( Figure 5F ). Treatment with TRAIL alone in this cell line reduced expression of Bcl-xL, though this effect was neither matched nor enhanced by CP-d/n-ATF5-S1
( Figure 5F ).
CP-d/n-ATF5-S1 sensitizes for TRAIL-mediated apoptosis at least in part by downregulating Bag3 and Mcl-1
Decreased expression of Mcl-1 following treatment with CP-d/n-ATF5-S1 represents a mechanism likely to contribute to the CP-d/n-ATF5-S1-mediated sensitization towards TRAIL. 
CP-d/n-ATF5-S1 significantly attenuates tumor growth in vivo
We next assessed the therapeutic efficacy of CP-d/n-ATF5-S1 in multiple murine xenograft models. U87MG glioblastoma, A375 melanoma, PC3 prostate cancer cells, PANC-1 pancreatic cancer cells and HCT116 colorectal cancer cells were implanted subcutaneously; MDA-MB-231 triple-negative breast cancer cells were implanted in the mammary fat pad; and GBM12 patientderived xenografts were implanted intracranially. Once tumors formed, mice were randomized and treated with CP-d/n-ATF5-S1, vehicle or penetratin peptide as outlined in Figure 6A fig. 13 and Suppl. fig. 14) . Moreover, in a GBM12 intracranial patient-derived xenograft model, animals treated with CP-d/n-ATF5-S1
showed a median survival of 38 days which was significantly prolonged compared to 22.5 days in animals receiving vehicle ( Figure 6A ). While the treatments used here affected tumor growth rate, for the most part, they did not result in statistically significant regression of tumors.
However, there was a statistically significant tumor regression in mice bearing MDA-MB-231 breast cancer mammary fat pad xenografts (Suppl. fig. 14E-G) . This effect was not observed when mice were treated with Penetratin alone (Suppl. fig. 14E -G).
To detect possible toxic effects due to peptide treatment, histological analysis was performed on various tumor-free tissues of animals treated with either vehicle or CP-d/n-ATF5-S1 according to the dosing schedule described in Figure 6C . No tissue alterations in brain, lung, kidney, heart, liver, spleen, and intestine were found (Suppl. fig. 15A ). Moreover, the body weights of the animals did not vary between the treatment groups toward the end of the experiment (Suppl. fig.   15B ).
Research. 
Combined treatment with CP-d/n-ATF5-S1 and ABT263 significantly enhances attenuation of tumor growth in vivo
Our in vitro studies indicated that combined CP-d/n-ATF5-S1 and ABT263 treatment enhanced tumor cell death due to additive and complementary effects on anti-apoptotic Bcl-2 family members. To assess whether the combination is more effective in vivo than either treatment alone, we utilized a U251 heterotopic glioblastoma xenograft model and a HCT116 heterotopic colorectal cancer xenograft model Figure 6D and Suppl. fig. 5C . The mice with xenografted tumors were divided into four groups: vehicle, ABT263, CP-d/n-ATF5-S1 or the combination of ABT263 and CP-d/n-ATF5-S1. As shown in Figure 6D , in the U251 model, at the end point of the study, animals that received the combination treatment had significantly smaller tumors compared to those treated either with ABT263 or CP-d/n-ATF5-S1 alone and showed a decrease in tumor size over time when compared to the beginning of treatment. Similarly, in the HCT116 model the combination treatment led to significant reduction in tumor growth rate when compared to vehicle or single-agent treatments (Suppl. fig. 5C ). The combination treatment also showed no clinical signs of toxicity, indicating that although the combined treatment is more efficient, it does not increase the occurrence of evident side effects.
Discussion
Cancer cells typically develop primary or secondary resistance to apoptosis (36). Therefore, means to manipulate the apoptotic machinery are pivotal to restore therapeutic sensitivity.
Deregulation of the apoptotic machinery is mediated through numerous factors, such as the Bcl-2 family of proteins, the Inhibitor of Apoptosis Proteins and expression of death receptors, initiator caspases and endogenous caspase inhibitors (37,38). The aberrant expression of such molecules is regulated by various means, including the actions of transcription factors. ATF5 is an example of a transcription factor with oncogenic potential that affects Bcl-2 family member expression (13,16). ATF5 is up-regulated in various malignancies, including highly prevalent tumors, such as breast carcinoma (11), but it is also increased in less common malignancies, such as low-and high-grade gliomas (13,16). In the context of low-and high-grade gliomas, ATF5 expression levels are not only increased, but also correlate with survival (13). Thus, ATF5
represents a potential target in treatment refractory cancers.
Here, we show that a novel synthetic cell penetrating dominant-negative ATF5 peptide induces apoptosis in a broad range of tumor types, including glioblastoma, triple-negative breast cancer Our findings show that in PC3, PANC-1, T98G, H1975, A375 and U87MG cells, CP-d/n-ATF5-S1 significantly affects protein levels of Usp9X starting as early as 48h and continuing at 72h after treatment, when apoptotic death is manifest. To assess the impact of Usp9X depletion by CP-d/n-ATF5-S1, we transfected glioblastoma cells with Usp9X siRNA and found that this was sufficient to induce significant apoptotic death. Mechanistically, Usp9X knockdown caused concomitant suppression of Bag3, Mcl-1 and Bcl-2 expression, which remarkably recapitulates the effects of CP-d/n-ATF5-S1 on these molecules. These observations suggest that CP-d/n-ATF5-S1-mediated suppression of Usp9X levels may be an instrumental mechanism by which it mediates death of neoplastic cells. While Usp9X is known to modulate Mcl-1 expression, our observed effects of Usp9X manipulation on Bag3 and Bcl-2 have not been previously described and may suggest that Usp9X also interacts with Bag3 as well as Bcl-2. The mechanism(s) by which CP-d/n-ATF5-S1 decreases Usp9X expression remain to be explored. Our data indicate a post-transcriptional mechanism in that the peptide does not affect Usp9X mRNA levels. The strong antineoplastic activity related to Usp9X down-regulation warrants further studies directed at identification of specific small-molecule inhibitors of Usp9X function.
Given our observation that CP-d/n-ATF5-S1 strongly affects the intrinsic apoptotic machinery and the possibility that treatment with a single drug may fall short in the clinic, we investigated whether rational drug combination therapies could enhance the efficacy of CP-d/n-ATF5-S1. For that purpose, we utilized the orally available BH3-mimetic ABT263 (43). This class of compounds has received great attention since they target both Bcl-2 and Bcl-xL, which are upregulated in many malignancies, especially in hematological malignancies, such as follicular These considerations led us to assess the combination of CP-d/n-ATF5-S1 and ABT263 in vitro and in in vivo xenograft tumor models. We found enhanced cell death by this combination in a variety of tumor cell lines, including LN229 and A375 that are relatively resistant to ABT263. In the in vivo models, the combination was highly effective compared with the single treatments and blocked/reduced tumor growth over the course of the studies.
Because the Bcl-2 family is also implicated in extrinsic apoptosis, we tested whether CP-d/n-ATF5-S1 overcomes resistance to TRAIL. TRAIL has received attention for its ability to kill a broad variety of cancer cells in vitro and in vivo. One main obstacle for TRAIL-related therapies is that while a subset of tumors respond, the majority display resistance (50). Therefore, efforts have aimed to identify treatments that sensitize cancer cells to TRAIL therapeutics. Our results suggest that CP-d/n-ATF5-S1 is a potent sensitizer for TRAIL-mediated apoptosis.
Mechanistically this is most likely linked to the ability of CP-d/n-ATF5-S1 to suppress Bag3 and Mcl-1, since specific knockdown of Bag3 or Mcl-1 was sufficient to sensitize TRAIL-resistant LN229 glioblastoma cells to apoptosis.
Overall, our results serve as a proof of principle and suggest that the strategy of treatment with a cell penetrating dominant-negative form of ATF5 is efficacious, selective and non-toxic and therefore holds promise for cancer therapy, either alone or in a multi-targeting approach. eIF2 directs ATF5 translational control in response to diverse stress conditions. J Biol 
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